Cargando…
A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience
Biologic drugs (e.g. anti-tumor necrosis factors) are effective treatments for multiple chronic inflammatory diseases including rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis. Administration of biologic drugs is usually via subcutaneous self-injection, which provides many pat...
Autores principales: | van den Bemt, Bart J. F., Gettings, Lynda, Domańska, Barbara, Bruggraber, Richard, Mountian, Irina, Kristensen, Lars E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442222/ https://www.ncbi.nlm.nih.gov/pubmed/30905213 http://dx.doi.org/10.1080/10717544.2019.1587043 |
Ejemplares similares
-
A Companion App to Support Rheumatology Patients Treated with Certolizumab Pegol: Results From a Usability Study
por: Domańska, Barbara, et al.
Publicado: (2020) -
Using Patient Feedback to Optimize the Design of a Certolizumab Pegol Electromechanical Self-Injection Device: Insights from Human Factors Studies
por: Domańska, Barbara, et al.
Publicado: (2017) -
From drug-delivery device to disease management tool: a study of preferences for enhanced features in next-generation self-injection devices
por: Boeri, Marco, et al.
Publicado: (2019) -
EULAR portfolio for Rheumatology training: a EULAR School of Rheumatology initiative
por: van Onna, Marloes, et al.
Publicado: (2021) -
Patient Satisfaction with CIMZIA(®) (Certolizumab Pegol) AutoClicks(®) in the UK
por: Bailey, Kathryn, et al.
Publicado: (2020)